hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06275035 id: 4235 briefTitle: Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI acronym: MEMENTO overallStatus: RECRUITING date: 2024-02-22 date: 2026-01 date: 2031-01 date: 2024-02-23 date: 2024-03-01 name: Tata Memorial Centre class: OTHER briefSummary: The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy. conditions: Neurocognitive Dysfunction studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 101 type: ESTIMATED name: Memantine Oral Tablet measure: Cognitive-deterioration-free survival at 2 years measure: Full-Scale Intelligence Quotient (FSIQ) in children measure: Overall survival (OS) measure: Academic performance by scholastic performance and grades measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of Memantine measure: Progression-Free Survival (PFS) measure: Full-Scale Intelligence Quotient (FSIQ) in adults measure: Full Scale Intelligence Quotient change in subgroups measure: Radiological features of cognitive decline on Magnetic Resonance Imaging measure: Neuroinflammatory markers correlation with neurocognitive decline and survival sex: ALL minimumAge: 5 Years maximumAge: 39 Years stdAges: CHILD stdAges: ADULT facility: Tata Memorial Hospital status: RECRUITING city: Mumbai state: Maharashtra zip: 400012 country: India name: Dr Tejpal Gupta, MD role: CONTACT phone: 022-24177000 phoneExt: 6015 email: tejpalgupta@rediffmail.com lat: 19.07283 lon: 72.88261 hasResults: False
nctId: NCT06275022 id: NanjingCH011665 briefTitle: A Prospective Study on the Treatment of cLM Based on ICG Imaging overallStatus: RECRUITING date: 2023-01-01 date: 2025-12-31 date: 2026-06-30 date: 2024-02-23 date: 2024-02-23 name: Nanjing Children's Hospital class: OTHER briefSummary: The goal of this prospective randomized controlled study is to explore the role of indocyanine green-fluorescence imaging in management of cystic lymphatic malformation.. To clarify the application value of indocyanine green-fluorescence imaging in both diagnosis and treatment of cystic lymphatic malformation (cLM) in children, is helpful for exploring pathogenesis of cLM, and providing a clearer scientific basis for subsequent surgical intervention. It also provides alternative for the future diagnosis and treatment of cLM.
Researchers will compare difference in curative effect between two groups. conditions: Lymphatic Malformation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 110 type: ESTIMATED name: Inflow occlusion with perforation of septation and sclerotherapy name: Perforation of septation and sclerotherapy name: Indocyanine green-guided partial resection and sclerotherapy name: Partial resection and sclerotherapy measure: Cure rate measure: Effective rate measure: Treatment frequency measure: Likert score measure: Wound infection measure: Delayed healing measure: Pigmentation sex: ALL minimumAge: 30 Days maximumAge: 16 Years stdAges: CHILD facility: Children's hospital of Nanjing medical university status: RECRUITING city: Nanjing state: Jiangsu zip: 210008 country: China name: Tao Han, Dr. role: CONTACT phone: +86 186 5190 3495 email: dr.hantao@njmu.edu.cn lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06275009 id: 2023-1990 briefTitle: Chinese Occupational Population Cohort of Lifestyle and Physical Fitness (LiFitChina) acronym: LiFitChina overallStatus: RECRUITING date: 2023-12-11 date: 2026-12-11 date: 2026-12-11 date: 2024-02-23 date: 2024-02-28 name: China National Center for Cardiovascular Diseases class: OTHER_GOV briefSummary: The incidence and prevalence of metabolic risk factors such as obesity, hypertension, diabetes, and dyslipidemia, as well as cardiovascular diseases (CVD), are continuously rising among the occupational population in China, primarily comprising the middle-aged and young adults. Unhealthy lifestyles and declining physical fitness are independent risk factors affecting cardiovascular health. Additionally, the level of physical fitness is influenced by postnatal lifestyles. Lifestyle factors related to cardiovascular health in the occupational population encompass various aspects, including smoking, physical activity, diet, sleep, psychological stress, etc. These factors may interact or have a synergistic effect, necessitating a comprehensive assessment.
This project proposes a prospective cohort study design to establish a monitoring cohort for lifestyle and physical fitness among the occupational population. The study will track and follow individuals with or without any CVD metabolic risk factors, collecting information on general status, lifestyle, physical fitness, and health examination data. Exposure factors such as lifestyle and physical fitness will be measured annually, and the occurrence of CVD-related health outcomes will be observed. The aim is to develop a comprehensive evaluation index for cardiovascular health lifestyle, analyze the direct and indirect impacts of lifestyle and physical fitness on the occurrence and development of CVD, and explore potential mediating and moderating effects of physical fitness in the association between lifestyle and cardiovascular health. conditions: Lifestyle conditions: Physical Fitness conditions: Cardiovascular Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 18512 type: ESTIMATED measure: the composite end point of new major adverse cardiovascular events measure: new incidence of each major adverse cardiovascular events measure: new incidence of cancer measure: new incidence of all-cause death measure: level of systolic pressure measure: level of diastolic pressure measure: level of blood lipid measure: level of BMI measure: level of maximal oxygen uptake (VO2max) measure: level of metabolic equivalents (METs) sex: ALL minimumAge: 18 Years maximumAge: 59 Years stdAges: ADULT facility: Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College status: RECRUITING city: Beijing state: Beijing country: China name: Xue Feng, MD PhD role: CONTACT phone: +86-15601378512 email: 29611290@qq.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06274996 id: 2024ZSLYEC-063 briefTitle: Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease overallStatus: COMPLETED date: 2021-01-01 date: 2023-12-31 date: 2023-12-31 date: 2024-02-23 date: 2024-02-23 name: Sixth Affiliated Hospital, Sun Yat-sen University class: OTHER briefSummary: This study focuses on evaluating Upadacitinib, a new oral medication that inhibits specific enzymes involved in inflammation, for treating inflammatory bowel disease (IBD), which includes conditions such as Crohn\'s Disease and Ulcerative Colitis. The goal is to determine how effective and safe this drug is for patients in China, where data is currently lacking.IBD significantly affects individuals\' quality of life and imposes a high burden on society and healthcare systems. Current treatments don\'t work for everyone, and some patients may need surgery. Upadacitinib has shown promise in other countries for treating IBD and related conditions and has been approved by the US FDA for such use.
Our study is retrospective and multicenter, meaning it will look back at patient records from multiple hospitals to analyze the outcomes of those who have received Upadacitinib. Investigators aim to enroll patients treated between January 2020 and December 2023, focusing on adults who have taken Upadacitinib for at least 8 weeks.For patients, families, and healthcare providers, this research could mean a potential new treatment option for IBD. Understanding Upadacitinib\'s efficacy and safety could lead to better management of the disease, possibly reducing the need for surgery and improving the quality of life for those affected by IBD. The ultimate goal is to provide more personalized and effective treatment strategies for IBD patients in China. conditions: Inflammatory Bowel Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 81 type: ACTUAL name: Upadacitinib measure: Steroid-Free Clinical Remission measure: Clinical Response measure: Endoscopic Remission measure: Mucosal Healing measure: Radiological remission measure: Radiological response sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the Sixth Affiliated Hospital of Sun Yat-Sen University city: Guangzhou state: Guangdong zip: 510655 country: China lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06274983 id: SCH-2629 briefTitle: DMD- Interactive Virtual Reality Study acronym: DMD-IVR overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-20 date: 2024-02-29 date: 2024-02-29 date: 2024-02-23 date: 2024-02-26 name: Sheffield Children's NHS Foundation Trust class: OTHER name: National Institute for Health Research, United Kingdom name: Sheffield Hallam University name: UCL Great Ormond Street Institute of Child Health name: Leeds General Infirmary briefSummary: This study will help determine if an Interactive Virtual Reality system can improve the physiotherapy of young patients with Duchenne muscular dystrophy (DMD). conditions: Duchenne Muscular Dystrophy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 14 type: ACTUAL name: IVR platform trial measure: Compliance: Ratings of frequency of the DMD-IVR device use for the participant's to complete recommended physiotherapy exercises. measure: Compliance: Ratings of duration of the DMD-IVR device use for the participant's to complete recommended physiotherapy exercises. measure: Post-trial qualitative interviews on perceptions, acceptability, usability and effectiveness of DMD-IVR device in the context of the family's overall burden of care measure: DMD-IVR Effectiveness standard functional assessments: North Star Ambulatory Assessment (NSAA) measure: DMD-IVR effectiveness measures with a Timed test 4 stair climb measure: DMD-IVR effectiveness measured joint range of movement using Goniometer (Standard BASELINE® 12-inch) sex: ALL minimumAge: 5 Years maximumAge: 10 Years stdAges: CHILD facility: Sheffield Childrens NHS FT city: Sheffield state: South Yorkshire zip: S10 2TH country: United Kingdom lat: 53.38297 lon: -1.4659 hasResults: False
nctId: NCT06274970 id: 2022-143-Mch-EXP-50 briefTitle: PaThERAS: ERAS Protocols in Thyroid & Parathyroid Surgery acronym: PaThERAS overallStatus: RECRUITING date: 2023-01-25 date: 2024-09-25 date: 2024-09-25 date: 2024-02-23 date: 2024-02-23 name: Sanjay Gandhi Postgraduate Institute of Medical Sciences class: OTHER_GOV briefSummary: Enhanced recovery after surgery protocols are evidence-based multidisciplinary programs implemented in the perioperative setting to improve postoperative recovery and attenuate the surgical stress response. They have been used with success after many different types of surgery to improve perioperative patient outcomes. However, evidence on their effectiveness in thyroid and parathyroid surgery remains sparse. Goal of PaThERAS study is to investigate the clinical benefits and cost-effectiveness of enhanced recovery protocols for the perioperative management in patients undergoing total thyroidectomy for large goiters/ cancers and parathyroidectomy for symptomatic hyperparathyroidism in non-day-care setting. conditions: Thyroid Diseases conditions: Parathyroid Diseases conditions: ERAS studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 110 type: ESTIMATED name: Enhanced recovery protocols name: Conventional Protocols measure: To compare the rate of hypocalcemia in patients undergoing thyroid and parathyroid surgery implementing Enhanced recovery after surgery protocols vs Conventional peri operative protocols measure: To compare length of hospital stay in patients undergoing thyroid and parathyroid surgery in days measure: To compare hospital costs in patients undergoing thyroid and parathyroid surgery implementing Enhanced recovery after surgery protocols vs Conventional peri operative protocols measure: To compare postoperative complication rates in patients undergoing thyroid and parathyroid surgery implementing Enhanced recovery after surgery protocols vs Conventional peri operative protocols measure: To compare readmission rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sanjay Gandhi Post Graduate Institute of Medical Sciences status: RECRUITING city: Lucknow state: Uttar Pradesh zip: 226014 country: India name: Gaurav Agarwal role: CONTACT phone: 8004904646 email: gauravbsi@gmail.com name: Rinelle Mascarenhas role: CONTACT phone: 8004904653 email: rmasky@hotmail.com name: Gaurav Agarwal, MS role: PRINCIPAL_INVESTIGATOR name: Rinelle Mascarenhas, DNB General Surgery role: SUB_INVESTIGATOR lat: 26.83928 lon: 80.92313 hasResults: False
nctId: NCT06274957 id: SaglikBilimleriUN briefTitle: The Effect of Airway and Chest Wall Oscillation on Respiratory Functions in COPD Patients in Acute Exacerbation overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-05-07 date: 2024-06-01 date: 2024-02-23 date: 2024-04-17 name: Saglik Bilimleri Universitesi class: OTHER name: Gulhane Training and Research Hospital briefSummary: Chronic obstructive pulmonary disease (COPD); It is a common, treatable and preventable disease characterized by progressive and irreversible airflow limitation and has systemic effects with respiratory system involvement. Increased respiratory workload, decreased work . conditions: COPD Exacerbation Acute studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 27 type: ESTIMATED name: CONTROL name: PEP DEVICE name: HFCWO DEVICE measure: COPD assessment test measure: Clinical COPD Questionnaire measure: mMRC dyspnea scale measure: Richard-Campbell Sleep Questionnaire measure: 30 second sit and stand measure: BODE index measure: chest circumference measurements measure: Modified Borg Scale measure: muscle strenght test sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Health Sciences city: Istanbul zip: 34353 country: Turkey name: ZUHAL KUNDURACILAR PROF DR role: CONTACT phone: +90 530 219 5286 email: zuhal.kunduracilar@sbu.edu.tr name: GAMZE KOYUTÜRK PT, PhD(c) role: CONTACT phone: +90 5065798671 email: gamzealtinkaynak@gmail.com name: GAMZE KOYUTÜRK PT, PhD (C) role: PRINCIPAL_INVESTIGATOR lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06274944 id: PEDS-2023-31694 briefTitle: Nasogastric/Orogastric Tube Placement Confirmation in Neonates Utilizing Self-contained pH Device, a Feasibility Study overallStatus: RECRUITING date: 2024-02-12 date: 2025-01-31 date: 2025-01-31 date: 2024-02-23 date: 2024-03-04 name: University of Minnesota class: OTHER briefSummary: This study is looking at using a self-contained pH device that will assist in confirming placement of a nasogastric or orogastric tube placed in the stomach of hospitalized infants. conditions: Premature Birth studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: nasogastric tube placement pH confirmation device measure: PH reading comparison sex: ALL maximumAge: 2 Years stdAges: CHILD facility: University of Minnesota status: RECRUITING city: Minneapolis state: Minnesota zip: 55414 country: United States name: Brittany Faanes role: CONTACT lat: 44.97997 lon: -93.26384 hasResults: False
nctId: NCT06274931 id: 373 briefTitle: Analysis of the Pulmonary Microbiome overallStatus: RECRUITING date: 2024-02-01 date: 2024-02-20 date: 2024-06-20 date: 2024-02-23 date: 2024-02-23 name: University Magna Graecia class: OTHER briefSummary: The purpose of the protocol is to study the pulmonary microbiome in patients who develop pneumonia. conditions: Pneumonia conditions: Microbial Colonization conditions: Microbial Disease studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Bronchoscopy measure: Assessment of Lung Microbiome in Acute Respiratory Failure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hosp[ital status: RECRUITING city: Catanzaro zip: 88100 country: Italy name: Andrea Bruni role: CONTACT phone: 3401414553 email: andreabruni@unicz.it lat: 38.88247 lon: 16.60086 hasResults: False
nctId: NCT06274918 id: 202111418 briefTitle: Reducing ESKAPE Transmission in the Operating Room overallStatus: RECRUITING date: 2023-02-01 date: 2024-06-01 date: 2024-12-01 date: 2024-02-23 date: 2024-02-23 name: University of Iowa class: OTHER name: RDB Bioinformatics, LLC name: Georgia-Pacific briefSummary: This study is designed to examine the impact of a personalized, body worn alcohol dispenser on the epidemiology of ESKAPE transmission in the anesthesia work area for patients undergoing surgery requiring general anesthesia. conditions: Surgical Procedure, Unspecified studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Personalized Body-Worn Alcohol Dispenser measure: ESKAPE transmission events with and without the body worn device measure: The epidemiology of ESKAPE transmission events measure: The epidemiology of ESKAPE transmission events measure: The epidemiology of ESKAPE transmission events measure: The epidemiology of ESKAPE transmission events measure: The epidemiology of ESKAPE transmission events measure: 90-Day Healthcare-Associated Infections sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Iowa status: RECRUITING city: Iowa City state: Iowa zip: 52242 country: United States name: Randy W Loftus, MD role: CONTACT lat: 41.66113 lon: -91.53017 hasResults: False
nctId: NCT06274905 id: 160123 briefTitle: Topical Anaesthesia in Cutaneous Head and Neck Surgery overallStatus: COMPLETED date: 2023-02-20 date: 2023-07-07 date: 2023-07-07 date: 2024-02-23 date: 2024-02-23 name: University Hospital Waterford class: OTHER briefSummary: This study aims to assess if EMLA or ethyl chloride spray are effective in reducing the pain associated with local anaesthetic administration in cutaneous surgery of the head and neck compared to a placebo and control group through a randomized control trial study design. conditions: Pain, Acute conditions: Head and Neck Cancer conditions: Cutaneous Tumor studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Single blinding (for participants) only for patients receiving EMLA or EMLA placebo. whoMasked: PARTICIPANT count: 124 type: ACTUAL name: EMLA name: Ethyl chloride name: Aqueous cream BP measure: Pain score measure: Patient satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Waterford city: Waterford zip: X91 ER8E country: Ireland lat: 52.25833 lon: -7.11194 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2022-12-20 uploadDate: 2024-02-06T12:37 filename: Prot_SAP_000.pdf size: 417714 hasResults: False
nctId: NCT06274892 id: 23-5818 briefTitle: Remote Monitoring of Patient Reported Outcomes to Improve the Efficacy of the Acute Phase Radiotherapy Review Process acronym: PROMOTE overallStatus: RECRUITING date: 2024-04-01 date: 2024-08-31 date: 2024-11-30 date: 2024-02-23 date: 2024-04-17 name: University Health Network, Toronto class: OTHER briefSummary: Radiation therapy (RT) is a key component in the treatment of breast and prostate cancer. However, patients may experience significant side effects. Patients can accurately self-report side effects from RT and these patient-reported outcomes (PROs) can direct communication between patient and healthcare provider (HCP), and facilitate joint decision making.
Currently, patients receiving RT are seen by a Radiation Oncologist once per week during RT and once every few months after RT has finished. Recent evaluations indicate that patients and physicians consider the number of visits to be too frequent during RT, and too infrequent immediately after RT. This research will use weekly mPROs (remotely monitored by RT HCP) to determine if a patient needs (or wants) to be seen by a RT HCP during and/or immediately after RT.
Using mPROs to optimize RT patient assessment processes will ensure patients are seen if and when required. For a patient, this could result in reduced time and costs at the hospital. For the physician, resources could be re-allocated to improve access to RT services. Using mPROs after RT has the potential for earlier treatment of side effects, which has been linked to improved survival and quality of life. conditions: Prostate Cancer conditions: Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 124 type: ESTIMATED name: Remote monitoring PROs measure: Remote monitoring efficiency measure: Remote monitoring efficacy measure: Remote monitoring value measure: Remote monitoring comprehensiveness measure: Influencing factors (patient) measure: Influencing factors (disease) measure: Influencing factors (treatment) measure: Influencing factors (toxicity) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Princess Margaret Cancer Centre status: RECRUITING city: Toronto state: Ontario zip: M5G 2J9 country: Canada name: Tara Rosewall role: CONTACT phone: 4162098269 email: tara.rosewall@rmp.uhn.ca name: Winnie Li role: CONTACT phone: 4169462000 email: winnie.li@uhn.ca lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06274879 id: 1938 Ablatio-bilica id: SNCPT type: OTHER domain: Portal for clinical trials in Switzerland briefTitle: Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer acronym: Ablatio overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-04-30 date: 2026-04-30 date: 2024-02-23 date: 2024-02-23 name: Insel Gruppe AG, University Hospital Bern class: OTHER name: Swiss Cancer League briefSummary: The goal of this clinical trial is to provide evidence for the general tolerability of radiofrequency ablation (bRFA) in patients with unresectable bile duct cancer undergoing systemic palliative treatment consisting of chemotherapy (gemcitabine and cisplatin) plus durvalumab (immune-checkpoint-inhibitor, ICI). The main question it aims to answer is whether it is safe to combine chemotherapy (gemcitabine and cisplatin) and immunotherapy (durvalumab) - CICI therapy.
Participants will be assigned to either the control group or the experimental group. In the control group, the standard of care consists of endoscopy with stent placement in the bile duct and CICI, whereas in the experimental group, bRFA will be performed in addition to the standard of care. Participants will be followed up for 6 months, during the follow-up, the stage of the tumor, blood examination, the duration of the stent from the insertion until its failure, adverse events and quality of life will be examined.